Penumbra PEN AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value

AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value at other companies

MedtronicMDT

——

Other financials

Income statement

See full

Revenue$374.8M+15.6%

Gross profit$253.4M+17.4%

Operating income$38.2M-5.2%

Net income$32.6M-16.9%

EPS (diluted)$0.82-18.0%

Balance sheet

See full

Cash & equivalents$241.3M-35.8%

Total debt$216.2M-2.0%

Total equity$1.5B+21.5%

Total assets$1.9B+19.2%

Cash flow

See full

Operating cash flow$87.0M+77.6%

CapEx$13.7M+1.5%

Free cash flow$73.3M+106%

Valuation

See full

Market cap$12.48B+25.1%

Enterprise value$12.45B+26.8%

P/E72.9×-163×

P/S8.6×+0.5×

Profitability

See full

Gross margin67.4%+3.7pp

Operating margin12.9%+9.8pp

Net margin11.8%+8.4pp

FCF margin14.6%+2.5pp

Returns & leverage

See full

Return on equity12.7%+9.2pp

Debt / equity0.1×0.0×

Current ratio6×-0.3×

Where this comes from

Reported directly by Penumbra in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger.

The official record: Penumbra’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Penumbra's afs and trading securities - unrealized loss position (>=12 months) fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Penumbra's AFS and trading securities - unrealized loss position (>=12 months) fair value?: Penumbra (PEN) reported AFS and trading securities - unrealized loss position (>=12 months) fair value of $0 in Q1 2026.